SynthesisMedical oncology (Northwood, London, England)2011
Lack of significant association between TGF-β1-590C/T polymorphism and breast cancer risk: a meta-analysis.
Synthesis in Medical oncology (Northwood, London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 3 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- SMAD7 polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies.Oncotarget · 2016Pooled it
- Association of TGF-β1 -509C/T polymorphisms with breast cancer risk: evidence from an updated meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection.Human genomics · 2013Pooled it
- Association ofCancers · 2020Article
- Effects of Two Common Promoter Polymorphisms of Transforming Growth Factor-β1 on Breast Cancer Risks in Ahvaz, West South of Iran.Iranian journal of cancer prevention · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transforming growth factor β1 (TGF-β1) is a cytokine that plays an important role in the control of cell proliferation and differentiation in breast cancer. The -509C/T polymorphism in the TGF-β1 gene has been implicated in breast cancer risk. However, studies on the association between this polymorphism and breast cancer risk have produced conflicting results. To derive a more precise estimation of the relationship, a meta-analysis of the -509C/T polymorphism (5,825 cases and 7,953 controls) from seven published case-control studies was performed. Our analysis suggests that -509C/T has no association with breast cancer risk when using either dominant [odds ratio (OR) = 1.01, 95% confidence intervals (CI): 0.82-1.24], or recessive models (OR = 0.91, 95% CI: 0.66-1.27), or other genetic models to analyze the data. In ethnic subgroups analysis, -509C/T also did not appear to be a risk factor for breast cancer. However, larger scale primary studies are still required to further evaluate the interaction of TGF-β1 -509C/T polymorphism and breast cancer risk in specific populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.